Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: There has been increasing interest in the detection of tumour exosomes in blood for cancer diagnostics. Most studies have focussed on miRNA and protein signatures that are surrogate markers for specific tumour types. Because tumour cells and tumour-derived exosomes display phosphatidylserine (PS) in their outer membrane leaflet, we developed a highly sensitive ELISA-based system that detects picogram amounts of exosomal phospholipid in plasma as a cancer biomarker.Methods: This report describes the development of a highly specific and sensitive ELISA for the capture of PS-expressing tumour exosomes in the blood of tumour-bearing mice. To monitor the relationship between tumour burden and tumour exosome plasma concentrations, plasma from one transplantable breast cancer model (MDA-MB-231) and three genetic mouse models (MMTV-PyMT; breast and KIC and KPC; pancreatic) were screened for captured exosomal phospholipid.Results: We show that quantitative assessment of PS-expressing tumour exosomes detected very early-stage malignancies before clinical evidence of disease in all four model systems. Tumour exosome levels showed significant increases by day 7 after tumour implantation in the MDA-MB-231 model while palpable tumours appeared only after day 27. For the MMTV-PyMT and KIC models, tumour exosome levels increased significantly by day 49 (≤0.0002) and day 21 (≤0.001) while tumours developed only after days 60 and 40, respectively. For the KPC model, a significant increase in blood exosome levels was detected by day 70 (P=0.023) when only preinvasive lesions are microscopically detectable.Conclusions: These data indicate that blood PS exosome levels is a specific indicator of cancer and suggest that blood PS is a biomarker for early-stage malignancies.

Original languageEnglish (US)
Pages (from-to)545-552
Number of pages8
JournalBritish Journal of Cancer
Volume117
Issue number4
DOIs
StatePublished - Aug 8 2017

Fingerprint

Exosomes
Phosphatidylserines
Neoplasms
Phospholipids
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • biomarker
  • ELISA
  • exosomes
  • phosphatidylethanolamine
  • phosphatidylserine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. / Sharma, Raghava; Huang, Xianming; Brekken, Rolf A.; Schroit, Alan J.

In: British Journal of Cancer, Vol. 117, No. 4, 08.08.2017, p. 545-552.

Research output: Contribution to journalArticle

@article{0eaab10a2074456c8cbec8d812581a15,
title = "Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies",
abstract = "Background: There has been increasing interest in the detection of tumour exosomes in blood for cancer diagnostics. Most studies have focussed on miRNA and protein signatures that are surrogate markers for specific tumour types. Because tumour cells and tumour-derived exosomes display phosphatidylserine (PS) in their outer membrane leaflet, we developed a highly sensitive ELISA-based system that detects picogram amounts of exosomal phospholipid in plasma as a cancer biomarker.Methods: This report describes the development of a highly specific and sensitive ELISA for the capture of PS-expressing tumour exosomes in the blood of tumour-bearing mice. To monitor the relationship between tumour burden and tumour exosome plasma concentrations, plasma from one transplantable breast cancer model (MDA-MB-231) and three genetic mouse models (MMTV-PyMT; breast and KIC and KPC; pancreatic) were screened for captured exosomal phospholipid.Results: We show that quantitative assessment of PS-expressing tumour exosomes detected very early-stage malignancies before clinical evidence of disease in all four model systems. Tumour exosome levels showed significant increases by day 7 after tumour implantation in the MDA-MB-231 model while palpable tumours appeared only after day 27. For the MMTV-PyMT and KIC models, tumour exosome levels increased significantly by day 49 (≤0.0002) and day 21 (≤0.001) while tumours developed only after days 60 and 40, respectively. For the KPC model, a significant increase in blood exosome levels was detected by day 70 (P=0.023) when only preinvasive lesions are microscopically detectable.Conclusions: These data indicate that blood PS exosome levels is a specific indicator of cancer and suggest that blood PS is a biomarker for early-stage malignancies.",
keywords = "biomarker, ELISA, exosomes, phosphatidylethanolamine, phosphatidylserine",
author = "Raghava Sharma and Xianming Huang and Brekken, {Rolf A.} and Schroit, {Alan J.}",
year = "2017",
month = "8",
day = "8",
doi = "10.1038/bjc.2017.1830",
language = "English (US)",
volume = "117",
pages = "545--552",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies

AU - Sharma, Raghava

AU - Huang, Xianming

AU - Brekken, Rolf A.

AU - Schroit, Alan J.

PY - 2017/8/8

Y1 - 2017/8/8

N2 - Background: There has been increasing interest in the detection of tumour exosomes in blood for cancer diagnostics. Most studies have focussed on miRNA and protein signatures that are surrogate markers for specific tumour types. Because tumour cells and tumour-derived exosomes display phosphatidylserine (PS) in their outer membrane leaflet, we developed a highly sensitive ELISA-based system that detects picogram amounts of exosomal phospholipid in plasma as a cancer biomarker.Methods: This report describes the development of a highly specific and sensitive ELISA for the capture of PS-expressing tumour exosomes in the blood of tumour-bearing mice. To monitor the relationship between tumour burden and tumour exosome plasma concentrations, plasma from one transplantable breast cancer model (MDA-MB-231) and three genetic mouse models (MMTV-PyMT; breast and KIC and KPC; pancreatic) were screened for captured exosomal phospholipid.Results: We show that quantitative assessment of PS-expressing tumour exosomes detected very early-stage malignancies before clinical evidence of disease in all four model systems. Tumour exosome levels showed significant increases by day 7 after tumour implantation in the MDA-MB-231 model while palpable tumours appeared only after day 27. For the MMTV-PyMT and KIC models, tumour exosome levels increased significantly by day 49 (≤0.0002) and day 21 (≤0.001) while tumours developed only after days 60 and 40, respectively. For the KPC model, a significant increase in blood exosome levels was detected by day 70 (P=0.023) when only preinvasive lesions are microscopically detectable.Conclusions: These data indicate that blood PS exosome levels is a specific indicator of cancer and suggest that blood PS is a biomarker for early-stage malignancies.

AB - Background: There has been increasing interest in the detection of tumour exosomes in blood for cancer diagnostics. Most studies have focussed on miRNA and protein signatures that are surrogate markers for specific tumour types. Because tumour cells and tumour-derived exosomes display phosphatidylserine (PS) in their outer membrane leaflet, we developed a highly sensitive ELISA-based system that detects picogram amounts of exosomal phospholipid in plasma as a cancer biomarker.Methods: This report describes the development of a highly specific and sensitive ELISA for the capture of PS-expressing tumour exosomes in the blood of tumour-bearing mice. To monitor the relationship between tumour burden and tumour exosome plasma concentrations, plasma from one transplantable breast cancer model (MDA-MB-231) and three genetic mouse models (MMTV-PyMT; breast and KIC and KPC; pancreatic) were screened for captured exosomal phospholipid.Results: We show that quantitative assessment of PS-expressing tumour exosomes detected very early-stage malignancies before clinical evidence of disease in all four model systems. Tumour exosome levels showed significant increases by day 7 after tumour implantation in the MDA-MB-231 model while palpable tumours appeared only after day 27. For the MMTV-PyMT and KIC models, tumour exosome levels increased significantly by day 49 (≤0.0002) and day 21 (≤0.001) while tumours developed only after days 60 and 40, respectively. For the KPC model, a significant increase in blood exosome levels was detected by day 70 (P=0.023) when only preinvasive lesions are microscopically detectable.Conclusions: These data indicate that blood PS exosome levels is a specific indicator of cancer and suggest that blood PS is a biomarker for early-stage malignancies.

KW - biomarker

KW - ELISA

KW - exosomes

KW - phosphatidylethanolamine

KW - phosphatidylserine

UR - http://www.scopus.com/inward/record.url?scp=85027023594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027023594&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.1830

DO - 10.1038/bjc.2017.1830

M3 - Article

VL - 117

SP - 545

EP - 552

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -